|
19 December 2002
FDA ADVISORY COMMITTEE REQUESTS FURTHER DATA ON ASTRAZENECA’S CASODEX® (BICALUTAMIDE) 150 MG
FOR EARLY PROSTATE CANCER
|
AstraZeneca announced today that the Oncologic Drugs Advisory Committee (ODAC) to the U.S. Food and Drug Administration (FDA) did not recommend approval of the new indication for CASODEX 150 mg for the treatment of early stage prostate cancer. The panel recommendation does not impact on the current use and approval of CASODEX 50 mg formulation, and also does not impact on CASODEX 150 mg approvals in other countries.
|
 |
12 December 2002
ASTRAZENECA WINS AUSTRALIA HIGH COURT APPEAL ON OMEPRAZOLE FORMULATION PATENT |
AstraZeneca today announced that the High Court of Australia has granted its appeal against an earlier Federal Court decision in a dispute with the generic pharmaceutical company, Alphapharm Pty Limited, about the validity of the formulation patent for omeprazole – the active substance used in Losec, a treatment for acid-related disorders, such as peptic ulcers.
|
|
11 December 2002
LATEST UPDATES FROM GROUNDBREAKING ATAC TRIAL CONFIRMS SUPERIORITY OF ARIMIDEX® OVER TAMOXIFEN IN EARLY BREAST CANCER |
AstraZeneca today announced from the San Antonio Breast Cancer Symposium in Texas, that the latest updates from the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial confirm the superior efficacy and favourable tolerability profile of ARIMIDEX over tamoxifen seen in as seen in the results reported last year.
|
|
9 December 2002
FIRST CHRONIC TREATMENT STUDY WITH ORAL EXANTA™ (XIMELAGATRAN) DEMONSTRATES HIGHLY SIGNIFICANT LONG TERM BENEFIT IN PREVENTING RECURRENT VENOUS THROMBOEMBOLISM (VTE) |
Additional data demonstrate superiority of EXANTA over both warfarin and enoxaparin in preventing VTE after major elective orthopaedic surgery
|
|
6 December 2002
NEW DATA DEMONSTRATES SYMBICORT® IS AN EFFECTIVE NEW TREATMENT FOR MODERATE TO SEVERE COPD |
AstraZeneca announced today that new data from a 12 month study presented at the British Thoracic Society (BTS) show that SYMBICORT® TURBUHALER® markedly reduces exacerbations and improves lung function in patients with moderate to severe chronic obstructive pulmonary disease (COPD), making it an important new treatment for this serious disease.
|
|
26 November 2002
ASTRAZENECA OPENS EAST ASIA CLINICAL RESEARCH CENTRE IN SHANGHAI |
AstraZeneca announced today the opening of its Clinical Research Unit-East Asia (ACRU-EA) in Shanghai.
|
|
21 November 2002
ASTRAZENECA APPOINTS NEW GROUP TREASURER |
Adrian Marsh will join AstraZeneca PLC, the international pharmaceuticals company, as Group Treasurer on January 1, 2003.
|
|
14 November 2002
ASTRAZENECA PLC – DIRECTORATE ANNOUNCEMENT |
AstraZeneca PLC today announced that Åke Stavling will be leaving the Company on 31 January 2003. Åke Stavling is 58 and has been an Executive Director since April 1999. He played a key role in the integration of Astra and Zeneca following the merger in 1999 and since then has been responsible for Business Development. From 1993-1999 he was Executive Vice President and Chief Financial Officer of Astra AB and before that held senior positions at Atlas Copco and Ericsson.
|
|
7 November 2002
ASTRAZENECA REPORTS SIGNIFICANT PROGRESS ACROSS ITS PROMISING RESEARCH AND DEVELOPMENT PORTFOLIO |
AstraZeneca today updated analysts on the company's late stage development products and projects; the progress of earlier stage products, notably in the cardio-vascular and oncology therapeutic areas; and the improved productivity in drug discovery, at its annual business review meeting in Alderley Park, Cheshire, UK, a centre of excellence for Oncology Research and Development at AstraZeneca.
|
|
7 November 2002
ASTRAZENECA’S NEW STATIN, CRESTOR™, RECEIVES FIRST APPROVAL IN EUROPE - Other European markets should follow in 2003 |
AstraZeneca announced today it has received the first approval for CRESTOR™ (rosuvastatin) 10-40 mg from the Medicines Evaluation Board (MEB) in the Netherlands for the management of primary hypercholesterolaemia and mixed dyslipidaemia.
|
|
5 November 2002
OMEPRAZOLE PATENT LITIGATION – ASTRAZENECA TO APPEAL US COURT’S JUDGEMENT RELATING TO KUDCo AND SCHWARZ PHARMA |
AstraZeneca’s initial detailed review of the Court’s October 11th 2002 opinion relating to KUDCo and Schwarz Pharma has revealed that the Court made reversible errors in determining key facts and applying the law. AstraZeneca has therefore decided to appeal the portions of the Court’s judgement relating to KUDCo and Schwarz Pharma.
|
|
28 October 2002
ASTRAZENECA’S NEW ORAL DIRECT THROMBIN INHIBITOR EXANTA™ SUPERIOR IN REDUCING RISK OF VENOUS THROMBOEMBOLISM (VTE) FOLLOWING TOTAL HIP OR KNEE REPLACEMENT SURGERY |
AstraZeneca announced today, from the 17th International Congress on Thrombosis (ICT) in Bologna, results from the EXPRESS phase III clinical trial with Exanta™ (oral ximelagatran and its active form, melagatran) that showed the drug’s superior efficacy in reducing risk of major venous thromboembolism (VTE) compared with a routinely used prophylactic treatment, enoxaparin, in major orthopaedic surgery.
|
|
24 October 2002
Third Quarter Results 2002 |
Download the
narrative
and the
figures.
|
|
22 October 2002
ASTRAZENECA LOSES UK APPEAL ON OMEPRAZOLE FORMULATION PATENTS |
AstraZeneca today announced that the Court of Appeal in London has denied its request for a re-trial following an earlier decision of the United Kingdom’s Patents Court in a dispute with the generic pharmaceutical companies, Arrow Generics Limited (acting through Cairnstores Limited) and Generics UK Limited, about formulation patents for omeprazole – the active substance used in Losec, a treatment for acid-related disorders, such as peptic ulcers.
|
|
25 September 2002
FDA ADVISORY COMMITTEE VOTES IN FAVOUR OF ACCELERATED APPROVAL OF ASTRAZENECA’S IRESSA® (ZD1839) FOR ADVANCED NON-SMALL-CELL LUNG CANCER |
AstraZeneca announced today that the Oncology Drugs Advisory Committee (ODAC) to the U.S. Food and Drug Administration (FDA) voted 11 to 3 that results in third line advanced non–small-cell lung cancer (NSCLC) were “reasonably likely to predict clinical benefit”, which the FDA indicated was a vote for accelerated approval for Iressa® (ZD1839) for the treatment of advanced NSCLC after disease progression following at least two chemotherapy agents (third line). The FDA will now review the ODAC recommendation and make their final determination regarding granting accelerated approval for ‘Iressa’. There are currently no approved drugs for this setting. Lung cancer is the leading cause of cancer deaths in the United States, and NSCLC accounts for 80 percent of all lung cancer cases.
|
|
16 September 2002
NEW SYMBICORT® DATA SHOW PROMISE FOR DRUG IN TWO NEW SETTINGS - ADJUSTABLE DOSING FOR ASTHMA AND
TREATMENT FOR COPD |
AstraZeneca announced today that new data presented at the 12th Annual Congress of the European Respiratory Society (ERS) show that adjustable dosing with Symbicort® provided effective asthma control using less drug overall than a fixed dosing regimen. An adjustable dosing approach with 'Symbicort' is a response to many asthma patients' needs and allows them to alter their dose according to disease variation using the same single inhaler. Additionally, nine poster presentations highlighted the ability of 'Symbicort' to significantly reduce the number of exacerbations and improve lung function in patients with Chronic Obstructive Pulmonary Disease (COPD).
|
|
6 September 2002
ASTRAZENECA GRANTED U.S. APPROVAL FOR ARIMIDEX® (anastrozole) IN EARLY BREAST CANCER |
AstraZeneca announced today that the U.S. Food and Drug Administration (FDA) has approved Arimidex® (anastrozole) for the adjuvant treatment of early breast cancer in postmenopausal women. The U.S. approval is based on the groundbreaking results from the ATAC (Arimidex, Tamoxifen, Alone or in Combination) study-the world's largest ever breast cancer trial - which showed significant efficacy and tolerability benefits of 'Arimidex' over tamoxifen in this setting.
|
|
1 September 2002
NEW DATA SHOW CRESTOR® MORE EFFECTIVE THAN ATORVASTATIN ACROSS A WIDE RANGE OF DOSES |
AstraZeneca announced today that data presented at the European Society of Cardiology Meeting in Berlin, show that Crestor® (rosuvastatin) consistently achieved a significantly greater reduction in LDL-Cholesterol (LDL-C) levels when compared to atorvastatin across the dose range tested. This marks the first presentation of data demonstrating the superior LDL-C lowering capability of 'Crestor' when compared with atorvastatin across a range of doses. Previously presented data have been individual dose comparisons or titration studies. AstraZeneca also announced the implementation of the GALAXY programme, which is a long-term comprehensive global research initiative to investigate cardiovascular risk reduction with 'Crestor'.
|
|
19 August 2002
LUNG CANCER TRIAL RESULTS SHOW NO IMPROVEMENT FOR THE COMBINED TREATMENT OF IRESSA (ZD1839) WITH STANDARD PLATINUM-BASED CHEMOTHERAPY. |
AstraZeneca Continues Seeking Approvals for Iressa Monotherapy in Lung Cancer.
|
|
7 August 2002
ASTRAZENECA COMPLETES NEW DRUG APPLICATION TO THE FDA FOR IRESSA™(ZD1839) TO TREAT NON-SMALL CELL LUNG CANCER |
AstraZeneca announced today that the final documents of the New Drug Application (NDA), for IRESSA™(ZD1839) have been submitted to the U.S. Food and Drug Administration (FDA) completing the rolling submission for the drug that began last summer. All clinical data including safety and efficacy information was provided to the agency in December. IRESSA™is being considered as a monotherapy agent for the treatment of advanced non-small cell lung cancer (NSCLC) after disease progression following chemotherapy.
|
|
6 August 2002
ASTRAZENECA UPDATE ON CRESTOR |
Following a constructive meeting with the US Food and Drug Administration (FDA) to discuss the company's response to the approvable letter for Crestor (rosuvastatin calcium), AstraZeneca has undertaken to provide further information from its ongoing study programme to supplement that already submitted.
|
|
25 July 2002
Half Year and Second Quarter Results 2002 |
Download the
narrative
and the
figures.
|
|
9 July 2002
WEALTH OF NEW DATA CONFIRMS EFFICACY AND SUITABILITY OF CRESTOR™ IN A WIDE-RANGE OF PATIENT POPULATIONS. More Patients Reach Target LDL-Cholesterol When Compared to Atorvastatin |
AstraZeneca announced today that the results of 14 data presentations for ‘Crestor’ (rosuvastatin) are being unveiled at the 73rd European Atherosclerosis Society congress in Salzburg, Austria this week. These include studies in comparisons with existing statins, which demonstrate that more patients reach target cholesterol levels with ‘Crestor’, in addition to other trials in a variety of patient populations.
|
|
8 July 2002
ASTRAZENECA COMPLETES MUTUAL RECOGNITION PROCEDURE FOR NEW PAEDIATRIC INDICATION FOR SYMBICORT® TURBUHALER® IN THE EUROPEAN UNION |
AstraZeneca announced today that it has successfully completed the Mutual Recognition Procedure (MRP) for the use of Symbicort® Turbuhaler® as a maintenance treatment for asthma in children (age 6-11 years) in the European Union (EU), Iceland and Norway.
|
|
5 July 2002
ASTRAZENECA SECURES FIRST MARKET APPROVAL FOR IRESSA™ IN JAPAN |
AstraZeneca announced today that 'Iressa' (ZD1839, gefitinib) 250 mg once daily has received approval for the treatment of inoperable or recurrent non-small cell lung cancer (NSCLC) from the Japanese Ministry of Health, Labour and Welfare (MHLW), making Japan the first country worldwide to licence the drug. 'Iressa' is the first in a new class of anti-cancer drugs, known as Epidermal Growth Factor Receptor (EGFR) inhibitors, to become commercially available.
|
|
26 June 2002
120,000 Swedish Twins Could Help Unlock the Secrets of the World's Diseases
|
AstraZeneca to Collaborate with the Karolinska Institute on New Bio Bank
|
|
21 June 2002
ASTRAZENECA RESPONDS TO FDA ACTION ON SUPPLEMENTAL NEW DRUG APPLICATION FOR CASODEX 150MG FOR EARLY PROSTATE CANCER |
AstraZeneca today announced that the US Food and Drug Administration (FDA) has issued a non-approvable letter for its supplemental new drug application (sNDA) for 'Casodex' (bicalutamide) 150mg for the treatment of early prostate cancer. The FDA's decision does not impact on the current use and approval of 'Casodex' 50mg formulation for advanced prostate cancer treatment.
|
|
17 June 2002
ASTRAZENECA AND AVENTIS COLLABORATE ON CLINICAL TRIALS PROGRAM FOR IRESSA™ (ZD1839) IN COMBINATION WITH TAXOTERE® (DOCETAXEL) OR CAMPTO® (IRINOTECAN) |
'Iressa', a once-daily, oral treatment, is a selective inhibitor of an enzyme known as EGFR-TK (epidermal growth factor receptor - tyrosine kinase), a new target for anti-cancer treatments, of which 'Iressa' is foremost in development. 'Iressa' specifically targets and blocks, within the cell, the activity of EGFR-TK, an enzyme that regulates intracellular signaling pathways implicated in cancer cell proliferation and survival. 'Iressa' is being developed by AstraZeneca and is not currently licensed in any country worldwide.
|
|
14 June 2002
AstraZeneca Opens New US$37.8 (£26) Million Tablets Expansion Facility To Cope With Growing Demand
|
AstraZeneca today opened a new US$ 37.8 million tablets expansion facility at its manufacturing site in Macclesfield, Cheshire, to provide further launch and growth capacity for treatments for serious medical disorders. One of its initial roles is in the manufacture of 'Seroquel' (quetiapine), for the treatment of schizophrenia.
|
|
6 June 2002
AstraZeneca and Pierre Fabre collaborate on clinical trial programme for IRESSA™ (ZD1839) in combination with Vinorelbine (NAVELBINE® ORAL) |
AstraZeneca and Pierre Fabre today announced their clinical collaboration to evaluate the benefits of 'Iressa' (ZD1839) in combination with Vinorelbine (NAVELBINE® ORAL) for the treatment of advanced non small cell lung cancer. The clinical collaboration, which will be jointly funded by the Companies, will initially assess the combination of 'Iressa' with NAVELBINE® ORAL as part of a Phase I/II clinical trial programme involving patients with advanced stage non-small cell lung cancer (NSCLC), and will then be considered for phase III.
|
|
5 June 2002
ASTRAZENECA RECEIVES FDA 'APPROVABLE' LETTER FOR CRESTOR™ |
AstraZeneca today confirms that it has received an "approvable" letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for 'Crestor' (rosuvastatin). The Company is reviewing its contents, and has no further comment at this time.
|
|
24 May 2002
ASTRAZENECA APPOINTS NEW R&D LEADERSHIP TEAM -
R&D Director to Retire
|
AstraZeneca today announced the appointment of Dr. Martin Nicklasson as Executive Vice President, Development, with responsibility for global drug development and Dr. Jan Lundberg, Executive Vice President, Discovery Research, responsible for all global discovery programmes. Both Dr. Nicklasson and Dr. Lundberg will join the company's Senior Executive Team and report to the Chief Executive, Tom McKillop. The appointments will take effect immediately following the planned retirement of Dr.Claes Wilhelmsson as a Director of AstraZeneca plc on 30th June 2002.
|
|
21 May 2002
ASTRAZENECA ANNOUNCES RESULTS FOR IRESSA ™ (ZD1839) IN ADVANCED HEAD AND NECK CANCER |
AstraZeneca today announced data from the first Phase II trial of 'Iressa' in patients with recurrent, advanced squamous cell cancer of the head and neck, whose disease had progressed following radiation and/or chemotherapy, at the American Society of Clinical Oncology (ASCO) 38th Annual Meeting in Orlando, Florida.
|
|
20 May 2002
Iressa ™ Study Results Confirm Efficacy in Advanced Non-small
Cell Lung Cancer
|
AstraZeneca announced today that the final phase II results from the pivotal 'Iressa' IDEAL ('Iressa' Dose Evaluation in Advanced Lung Cancer) 1 and 2 studies presented at the American Society of Clinical Oncology (ASCO) 38th Annual Meeting in Orlando, Florida, confirm 'Iressa' as an effective, potential new treatment approach, with a favourable tolerability profile for many patients with advanced non-small cell lung cancer (NSCLC). Additional data on 'Iressa' in patients with recurrent, advanced squamous cell cancer of the head and neck, whose disease has progressed following radiation and/or chemotherapy, will be presented tomorrow (Tuesday, May 21).
|
|
16 May 2002
ASTRAZENECA AND SHIONOGI TO CO - MARKET CRESTOR™ – A NEW CHOLESTEROL LOWERING TREATMENT – IN JAPAN |
AstraZeneca and Shionogi & Co. Ltd. today announced an agreement to co-market CRESTOR™, a new treatment for dyslipidaemia, in Japan.
|
|
6 May 2002
CRESTOR™ DATA AT WORLD CONGRESS OF CARDIOLOGY REINFORCE STRONG PRODUCT PROFILE |
Data were presented from two comparative studies involving a total of nearly 1,000 patients with hypercholesterolaemia. In both studies, changes in LDL-C levels (a major risk-factor for the development of CHD) and achievement of ATP-III LDL-C goals were assessed after a 12-week treatment period in patients receiving ‘Crestor’ 5 or 10mg compared with patients receiving pravastatin 20mg or simvastatin 20mg. The two studies were planned to enable the data to be analysed together.
|
|
1 May 2002
PHARMACEUTICAL INDUSTRY LEADERS ELECTED FELLOWS OF ACADEMY OF MEDICAL SCIENCES |
Dr. Tom McKillop, Chief Executive of AstraZeneca, and Dr. Barry Furr, Chief Scientist and Head of Project Evaluation for AstraZeneca, have been elected Fellows of the Academy of Medical Sciences, a member of the influential grouping of UK national Academies, and are now entitled to use the designation FMedSci.
|
|
26 April 2002
ASTRAZENECA RECEIVES FDA APPROVAL FOR FASLODEX - A NEW TYPE OF BREAST CANCER TREATMENT |
AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for its new breast cancer drug 'Faslodex'
for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antioestrogen therapy, (e.g. tamoxifen).
|
|
25 April 2002
ASTRAZENECA PLC FIRST QUARTER RESULTS 2002 |
Download the
narrative
and the
figures
|
|
25 April 2002
ASTRAZENECA PLC ANNOUNCES THE RESULTS OF THE POLLS TAKEN AT ITS ANNUAL GENERAL MEETING ON 25 APRIL 2002 |
AstraZeneca PLC announces the results of the polls taken at its Annual General Meeting today in respect of Items 9, 10 and 11 on the Agenda, as follows:
|
|
24 April 2002
ASTRAZENECA WINS LOSEC® PATENT CASE IN CANADA |
The Appeal Division of the Federal Court of Canada, has ruled in favour of AstraZeneca in litigation between AstraZeneca and RhoxalPharma Inc. under the Patented Medicines (Notice Of Compliance) Regulations.
|
|
15 April 2002
ARIMIDEX RECEIVES FDA PRIORITY REVIEW FOR EARLY BREAST CANCER INDICATION |
AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has granted a six-month Priority Review Status to the supplemental new drug application (sNDA) for Arimidex in the adjuvant treatment of early breast cancer in postmenopausal women. AstraZeneca filed the sNDA for Arimidex with the FDA on March 4, 2002, through a ‘fast track’ submission process. Priority Review Status is granted for new drugs or indications that represent a significant improvement in efficacy or safety over existing treatments.
|
|
8 April 2002
ARIMIDEX SUBMITTED FOR EARLY BREAST CANCER
LICENCE EXTENSION IN EUROPE |
AstraZeneca announced today that it has filed for a licence extension for Arimidex, for the treatment of postmenopausal women with early-stage breast cancer, via the European Union (EU) Mutual Recognition Procedure, with the United Kingdom as reference member state. Arimidex is already licensed worldwide for use in postmenopausal women with advanced disease.
|
|
18 March 2002
ASTRAZENECA PLC: BOARD APPOINTMENTS AND NOMINATIONS |
AstraZeneca PLC announced today:
|
|
13 March 2002
FIFTY UNDERGRADUATE STUDENTS AT 23 UNIVERSITIES TO BENEFIT FROM
ASTRAZENECA BURSARY PROGRAMME - £200,000 BOOST FOR CHEMISTRY EDUCATION IN UNITED KINGDOM
|
AstraZeneca announced today a bursary programme worth at least £200,000 for students working toward a first degree in chemistry. Financial support, in the amount of £1,000 each year, will be provided to 50 students starting their studies in October 2002 at universities across the UK.
|
|
6 March 2002
ASTRAZENECA TO SEEK LEAVE TO APPEAL OMEPRAZOLE PATENT DECISION IN UK COURT |
AstraZeneca today announced that it will seek leave to appeal against a decision by the Patents Court of the High Court of Justice’s Chancery Division in London that two of its formulation patents for omeprazole, the active ingredient in Losec, are invalid following legal challenges by two UK-based generic pharmaceutical companies.
|
|
4 March 2002
ASTRAZENECA PUBLIC OFFER TO PURCHASE REMAINING SHARES IN ASTRAZENECA PHARMA INDIA LTD |
AstraZeneca PLC today announced that its subsidiary Astra Pharmaceuticals AB is to make a voluntary public offer in India to purchase the 43.5% of shares in AstraZeneca Pharma India Limited, which it does not already own.
|
|
4 March 2002
ASTRAZENECA INVESTS $66 MILLION IN A NEW NEXIUM PRODUCTION FACILITY IN SÖDERTÄLJE, SWEDEN |
AstraZeneca is investing $66 million in a new production facility for Nexium Intravenous (IV) at one of its major production sites in Södertälje, Sweden. The capital expenditure provides a new state of the art facility for production of Nexium vials. It also incorporates essential infrastructure to support the manufacturing operations.
|
|
20 February 2002
ASTRAZENECA RECEIVES FDA PRIORITY REVIEW FOR CASODEX 150 MG FOR THE TREATMENT OF EARLY STAGE PROSTATE CANCER |
AstraZeneca announced today that the U.S. Food and Drug Administration (FDA) has granted a six-month priority review for the Supplemental New Drug Application (sNDA) of its oral, once-daily hormonal medication Casodex (bicalutamide 150mg) for the treatment of early stage non-metastatic prostate cancer.
|
|
31 January 2002
ASTRAZENECA PLC FOURTH QUARTER AND END-OF-YEAR RESULTS 2001
|
Download the
narrative
and the
figures
|
|
28 January 2002
ASTRAZENECA SUBMITS NDA IN JAPAN FOR IRESSA (ZD1839) – A NEW CLASS OF ANTI-CANCER TREATMENT |
AstraZeneca today announced the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) supporting the use of IRESSA for the treatment of non-small cell lung cancer (NSCLC). IRESSA is the first epidermal growth factor (EGFR) inhibitor to be filed in Japan. This means that the drug is now currently under regulatory review in two major global markets including the US.
|
|
17 January 2002
ASTRAZENECA OBTAINS REGULATORY APPROVAL FOR ZOLADEX® LA IN JAPAN |
AstraZeneca announced today that Zoladex® LA (goserelin acetate 10.8mg) for prostate cancer treatment has received marketing approval in Japan. This follows a positive report made by Japan’s Ministry of Health, Labour and Welfare’s (MHLW) Pharmaceutical Affairs Council in December 2001. Zoladex LA (Longer Acting) is the first Luteinizing Hormone-Releasing Hormone analogue (LHRHa) available in Japan with an injection that is effective for three months, and adds to the 3.6mg depot (monthly) formulation, already widely used. The approved indication in Japan is for the treatment of prostate cancer.
|
|
15 January 2002
FDA TO ‘FAST TRACK’ EXTENDED LICENCE APPLICATION FOR
ARIMIDEX® IN EARLY BREAST CANCER |
AstraZeneca announced today that the U.S. Food and Drug Administration (FDA) has granted ‘fast track’ status for the supplementary licence application of the Company’s aromatase inhibitor, Arimidex®, for the treatment of post-menopausal women with early breast cancer. This decision follows the exciting first results from the ATAC (Arimidex, Tamoxifen, Alone or in Combination) study of over 9,300 women, which showed that Arimidex is significantly more effective and has important tolerability benefits compared with the current gold standard, tamoxifen, as an adjuvant treatment in postmenopausal women with early breast cancer. Arimidex is already licensed for use in advanced disease.
|
|
3 January 2002
ASTRAZENECA COMPLETES EUROPEAN UNION MUTUAL RECOGNITION PROCEDURE FOR OXIS® TURBUHALER® * |
AstraZeneca announced today that it has successfully completed the Mutual Recognition Procedure (MRP) on 21 December 2001 for the use of Oxis® Turbuhaler® (formoterol) as a maintenance treatment for asthma in children (6 years and older) in 14 European Union (EU) states. **
|
|